Literature DB >> 4039929

Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia.

I Leprán, A M Lefer.   

Abstract

The effect of platelet-activating factor (PAF) was studied during the acute phase of myocardial ischemia in cats. PAF infusion (0.75 micrograms/kg/h for 4.5h) in anesthetized, open-chest cat decreased arterial blood pressure, but did not influence heart rate or biochemical indices of cell integrity. The same dose of PAF, however, started 30 min after coronary ligation, resulted in a significantly higher elevation of plasma creatine phosphokinase (CK) activity and a reduced CK content in the region of the ischemic myocardium. Treatment with the thromboxane A2 synthetase inhibitor, CGS-13080, significantly attenuated the PAF-aggravated ischemic cellular damage. These experiments suggest that hypoxia-generated PAF may contribute to the aggravation of myocardial ischemia, part of which appears to be due to PAF-induced release of thromboxane A2.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4039929     DOI： 10.1007/bf01910460

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN： 0300-8428            Impact factor:   17.165


  24 in total

1.  The role of platelet-activating factor in platelet aggregation.

Authors:  M Chignard; J P Le Couedic; M Tence; B B Vargaftig; J Benveniste
Journal:  Nature       Date:  1979-06-28       Impact factor: 49.962

2.  Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia.

Authors:  A M Lefer; M L Ogletree; J B Smith; M J Silver; K C Nicolaou; W E Barnette; G P Gasic
Journal:  Science       Date:  1978-04-07       Impact factor: 47.728

3.  Antihypertensive activity of an alkyl ether analog of phosphatidylcholine.

Authors:  M L Blank; F Snyder; L W Byers; B Brooks; E E Muirhead
Journal:  Biochem Biophys Res Commun       Date:  1979-10-29       Impact factor: 3.575

4.  Paf-acether (platelet-activating factor) increases microvascular permeability and affects endothelium-granulocyte interaction in microvascular beds.

Authors:  J Björk; L Lindbom; B Gerdin; G Smedegård; K E Arfors; J Benveniste
Journal:  Acta Physiol Scand       Date:  1983-11

5.  Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit.

Authors:  L M McManus; D J Hanahan; C A Demopoulos; R N Pinckard
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

6.  Glucocorticoid protection against PAF-acether toxicity in mice.

Authors:  A Myers; E Ramey; P Ramwell
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

7.  Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.

Authors:  A M Lefer; E F Smith; H Araki; J B Smith; D Aharony; D A Claremon; R L Magolda; K C Nicolaou
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor.

Authors:  S E Burke; G DiCola; A M Lefer
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

9.  Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea pig.

Authors:  M Chignard; F Wal; J Lefort; B B Vargaftig
Journal:  Eur J Pharmacol       Date:  1982-02-19       Impact factor: 4.432

10.  Continuous measurements of ATP secretion in vivo.

Authors:  J B Smith; S E Burke; A M Lefer; A Freilich
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200
View more
  7 in total

1.  Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart.

Authors:  G Montrucchio; G Alloatti; F Mariano; R de Paulis; A Comino; G Emanuelli; G Camussi
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

2.  Molecular and cellular actions of platelet-activating factor in rat heart cells.

Authors:  C V Massey; T A Kohout; S T Gaa; W J Lederer; T B Rogers
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

Review 3.  Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events.

Authors:  Vijay Nambi; Christie M Ballantyne
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

Review 4.  The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis.

Authors:  Salim S Virani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

5.  Inhibition of PAF-acether effects on isolated guinea pig hearts by zinc ions (Zn2+).

Authors:  A Evangelou; V Kalfakakou; J Benveniste; B Arnoux
Journal:  Biol Trace Elem Res       Date:  1995-10       Impact factor: 3.738

6.  Vitamin E. deficiency increases the synthesis of platelet-activating factor (PAF) in rat polymorphonuclear leucocytes.

Authors:  K Fukuzawa; Y Kurotori; A Tokumura; H Tsukatani
Journal:  Lipids       Date:  1989-03       Impact factor: 1.880

Review 7.  The pathophysiological role and therapeutic implications of platelet activating factor in diseases of aging.

Authors:  C Kroegel; C Kortsik; N Kroegel; H Matthys
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.